Publications by authors named "Jean Hoffman-Censits"

51Publications

Site of metastatic recurrence impacts prognosis in patients with high-grade upper tract urothelial carcinoma.

Urol Oncol 2021 Jan 15;39(1):74.e9-74.e16. Epub 2020 Oct 15.

Department of Urology, The James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, MD.

View Article and Find Full Text PDF
January 2021

Understanding Psychosocial and Sexual Health Concerns Among Women With Bladder Cancer Undergoing Radical Cystectomy.

Urology 2020 Aug 25. Epub 2020 Aug 25.

The James Buchanan Brady Urological Institute and Department of Urology, Johns Hopkins University School of Medicine, Baltimore, MD.

View Article and Find Full Text PDF
August 2020

Reply by Authors.

J Urol 2020 04 22;203(4):697-698. Epub 2020 Jan 22.

Department of Medical Oncology, Thomas Jefferson University, Philadelphia, Pennsylvania.

View Article and Find Full Text PDF
April 2020

Recent developments in the treatment of advanced bladder cancer.

Urol Oncol 2018 03 1;36(3):109-114. Epub 2018 Feb 1.

Department of Hematology/Oncology, Fox Chase Cancer Center, Temple Health, Philadelphia, PA.

View Article and Find Full Text PDF
March 2018

Recurrent renal cell carcinoma presenting as a solitary left ventricular mass.

Can J Urol 2017 Dec;24(6):9145-9147

Department of Medical Oncology, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, USA.

View Article and Find Full Text PDF
December 2017

Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017.

J Clin Oncol 2018 02 13;36(4):414-424. Epub 2017 Dec 13.

Veda N. Giri, Karen E. Knudsen, William K. Kelly, Robert B. Den, Adam P. Dicker, Jean Hoffman-Censits, Mark D. Hurwitz, Colette Hyatt, Grace Lu-Yao, Mark J. Mann, James R. Mark, Peter A. McCue, Ronald E. Myers, Stephen C. Peiper, Edouard J. Trabulsi, and Leonard G. Gomella, Jefferson Sidney Kimmel Cancer Center; Justin E. Bekelman, University of Pennsylvania Perelman School of Medicine; S. Bruce Malkowicz, University of Pennsylvania; Elias Obeid and Robert Uzzo, Fox Chase Cancer Center; Gordon F. Schwartz, Foundation for Breast and Prostate Health, Philadelphia; Mark S. Shahin, Hanjani Institute for Gynecologic Oncology, Abington Hospital-Jefferson Health, Abington, PA; Wassim Abida, Philip Kantoff, and Mark E. Robson, Memorial Sloan Kettering Cancer Center; Mitchell C. Benson, Columbia University, New York, NY; Gerald L. Andriole, Washington University School of Medicine, St Louis, MO; Chris H. Bangma, Erasmus Medical Center, Rotterdam, the Netherlands; Amie Blanco, and Matthew Cooperberg, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco; Christopher J. Kane, University of California San Diego, San Diego; Howard Sandler, Cedars-Sinai Medical Center, Los Angeles; Howard R. Soule, Prostate Cancer Foundation, Santa Monica, CA; Arthur Burnett, William B. Isaacs, Christian P. Pavlovich, and Patrick C. Walsh, Johns Hopkins Medical Institutions, Baltimore; Peter A. Pinto and Carol J. Weil, National Cancer Institute, Bethesda, MD; William J. Catalona and Edward Schaeffer, Northwestern University Feinberg School of Medicine; Scott Eggener, Sarah M. Nielsen, and Donald J. Vander Griend, University of Chicago, Chicago, IL; Kathleen A. Cooney, University of Utah School of Medicine, Salt Lake City, UT; David E. Crawford, University of Colorado, Aurora; Lawrence I. Karsh, The Urology Center of Colorado, Denver; Wendy Poage, Prostate Conditions Education Council, Elizabeth, CO; Neil Fleshner, University of Toronto Princess Margaret Cancer Centre, Toronto, Ontario, Canada; Matthew L. Freedman, Kevin R. Loughlin, and Timothy R. Rebbeck, Dana Farber Cancer Institute, and Harvard TH Chan School of Public Health, Boston, MA; Freddie C. Hamdy, University of Oxford, Oxford, England; R. Jeffrey Karnes, Mayo Clinic, Rochester, MN; Eric A. Klein, Cleveland Clinic, Cleveland; Robert Pilarski, The Ohio State University, Columbus, OH; Daniel W. Lin, University of Washington, Seattle, WA; Martin M. Miner, Brown University, Providence, RI; Todd Morgan and Scott A. Tomlins, University of Michigan, Ann Arbor; Matt T. Rosenberg, Mid-Michigan Health Center, Jackson, MI; Judd W. Moul, Duke University, Duke Cancer Institute, Durham, NC; David F. Penson, Vanderbilt University Medical Center, Nashville, TN; Daniel Petrylak and Brian Shuch, Yale University, New Haven, CT; Curtis A. Pettaway, The University of Texas MD Anderson Cancer Center, Houston; Ganesh V. Raj, University of Texas Southwestern Medical Center at Dallas, Dallas, TX; Oliver Sartor, Tulane University Medical School, New Orleans, LA; Neal D. Shore, Atlantic Urology Clinics/Carolina Urologic Research Center, Myrtle Beach, SC; and Richard Wender, American Cancer Society, Atlanta, GA.

View Article and Find Full Text PDF
February 2018

Cabazitaxel in the treatment of metastatic castration-resistant prostate cancer: patient selection and special considerations.

Onco Targets Ther 2017 17;10:4089-4098. Epub 2017 Aug 17.

Department of Medical Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, USA.

View Article and Find Full Text PDF
August 2017

Response to Pembrolizumab in a Patient With Chemotherapy Refractory Bladder Cancer With Small Cell Variant Histology: A Case Report and Review of the Literature.

Clin Genitourin Cancer 2017 06 22;15(3):e521-e524. Epub 2016 Dec 22.

Department of Medical Oncology, Sidney Kimmel Cancer Center, Jefferson University Hospital, Philadelphia, PA. Electronic address:

View Article and Find Full Text PDF
June 2017

Combination immunotherapy in genitourinary malignancies.

Curr Opin Urol 2016 11;26(6):523-8

Department of Medical Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, USA.

View Article and Find Full Text PDF
November 2016

Perioperative and Maintenance Therapy After First-Line Therapy as Paradigms for Drug Discovery in Urothelial Carcinoma.

Clin Genitourin Cancer 2015 Aug 26;13(4):302-308. Epub 2015 Mar 26.

Department of Medical Oncology, Fox Chase Cancer Center, Temple University Health System, Philadelphia, PA. Electronic address:

View Article and Find Full Text PDF
August 2015

Hematologic Toxicity of Concurrent Administration of Radium-223 and Next-generation Antiandrogen Therapies.

Am J Clin Oncol 2017 Aug;40(4):342-347

Departments of *Radiation Oncology †Medical Oncology ‡Urology, Kimmel Cancer Center, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA.

View Article and Find Full Text PDF
August 2017

Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin is safe, effective, and efficient neoadjuvant treatment for muscle-invasive bladder cancer: results of a multicenter phase II study with molecular correlates of response and toxicity.

J Clin Oncol 2014 Jun 12;32(18):1895-901. Epub 2014 May 12.

Elizabeth R. Plimack, Rosalia Viterbo, Eric A. Ross, Richard E. Greenberg, David Y.T. Chen, Yu-Ning Wong, Alexander Kutikov, Efrat Dotan, Essel Dulaimi, Reza Mehrazin, Robert G. Uzzo, and Gary R. Hudes, Fox Chase Cancer Center, Temple Health; Jean H. Hoffman-Censits, Edouard J. Trabulsi, Costas D. Lallas, Jianqing Lin, and William Kevin Kelly, Thomas Jefferson University Hospital, Philadelphia, PA; Timothy A. Brennan and Norma Palma, Foundation Medicine, Cambridge, MA; and Stephen A. Boorjian, Mayo Clinic, Rochester, MN.

View Article and Find Full Text PDF
June 2014

Practical guide to the use of enzalutamide.

Can J Urol 2014 Apr;21(2 Supp 1):64-9

Jefferson Medical College of Thomas Jefferson University, Philadelphia, Pennsylvania, USA.

View Article and Find Full Text PDF
April 2014

Chemotherapy and targeted therapies: are we making progress in castrate-resistant prostate cancer?

Semin Oncol 2013 Jun;40(3):361-74

Department of Medical Oncology, Thomas Jefferson University Hospital, Philadelphia, PA 19107, USA.

View Article and Find Full Text PDF
June 2013

Enzalutamide: a novel antiandrogen for patients with castrate-resistant prostate cancer.

Clin Cancer Res 2013 Mar 8;19(6):1335-9. Epub 2013 Jan 8.

Department of Medical Oncology, Thomas Jefferson University and Hospital, Philadelphia, Pennsylvania 19107, USA.

View Article and Find Full Text PDF
March 2013

Physician beliefs and practices for adjuvant and salvage radiation therapy after prostatectomy.

Int J Radiat Oncol Biol Phys 2012 Feb 24;82(2):e233-8. Epub 2011 May 24.

Department of Radiation Oncology, Jefferson Medical College, Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA 19107, USA.

View Article and Find Full Text PDF
February 2012

Chemotherapy for penile and urethral carcinoma.

Urol Clin North Am 2010 Aug;37(3):467-74

Department of Urology, Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA 19107, USA.

View Article and Find Full Text PDF
August 2010